

New Drug, Generic, and Biosimilar Pipeline Report

Q3 2026

Below is a summary of significant forthcoming drug launches of newly approved brand drugs, generics, and biosimilars.

New Drug Pipeline

GENERIC NAME	BRAND NAME (Manufacturer if drug name unavailable)	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED COST	THERAPEUTIC AREA	SPECIALTY OR TRADITIONAL
tavapadon	(Pfizer / Abbvie)	Oral	Q3 2026	\$10,000 - \$20,000 annually	Parkinson's Disease	Traditional
furosemide	Furoscix ReadyFlow Autoinjector (Mannkind)	Subcutaneous	Q3 2026	\$8,100 (per four-day treatment)	Nephrology	Traditional
TRN-257	(Tris Pharma)	Oral	2026	\$100,000 - \$200,000 annually	Sleep	Specialty
imsidolimab	(AnaptysBio; Vanda Pharmaceuticals)	Intravenous; Subcutaneous	2026	\$200,000 - \$300,000 annually	Dermatology	Specialty
insulin efsitora alfa	(Eli Lilly)	Subcutaneous	2026	\$5,000	Endocrinology	Traditional
furosemide	Furoscix ReadyFlow Autoinjector (Mannkind)	Subcutaneous	Q3 2026	\$8,100 (per four-day treatment)	Nephrology	Traditional
aficamten	Myqorzo (Cytokinetic)	Oral	2026	\$108,400	Cardiology	Specialty
dexmedetomidine	Igalmi (BioXcel Therapeutics)	Oral	2027	\$105 (per ten tablets)	Psychology	Traditional

Generic Pipeline

DRUG NAME	BRAND NAME	ROUTE OF ADMINISTRATION	STATUS / EST LOE PROB	ESTIMATED	THERAPEUTIC AREA	BIOSIMILAR OR TRADITIONAL
bupropion hydrobromide	Aplenzin	Oral	2026	226	Psychology	Traditional
Treprostinil	Tyvasio	Inhalation	2026	771	Pulmonology	Specialty
Linagliptin	Tradjenta	Oral	2026	1,350	Endocrine: Diabetes	Traditional
Vortioxetine	Trintellix	Oral	2026	1,424	Psychology	Traditional

Key

Launched MM YYYY Month and year drug was launched
Approved MM YYYY Month and year drug was approved
Date Updated release date

Withdrawn

CRL

EST LOE PROB

Drug has been withdrawn from FDA approval

Complete Response Letter - Incomplete FDA Application

Estimated Loss of Exclusivity Probability based on IPD Analytics' proprietary estimate of the probability of a generic launch, based on patent analysis and knowledge of generic launches

Biosimilar Pipeline

Generic Name	Brand Name (Manufacturer if drug name unavailable)	Route of Administration	Status	Estimated Cost	Therapeutic Area	Biosimilar or Traditional
Tocilizumab SC	Acterma	Subcutaneous	2026	1,200	Autoimmune	Biosimilar
abatacept	Orencia	Subcutaneous	2026	5,700	Autoimmune	Biosimilar
omalizumab	Xolair	Subcutaneous	2026	5,100	Autoimmune	Biosimilar
Insulin aspart	Novolog	Subcutaneous	2026	1,100	Endocrine: Diabetes	Traditional
Insulin lispro	Humalog	Subcutaneous	2026	1,600	Endocrine: Diabetes	Traditional
OnabotulinumtoxinA	Botox	Intramuscular	2027	3,500	Neurology	Traditional

Nothing herein is or shall be construed as a promise or representation regarding past or future events and Serve You Rx expressly disclaims any and all liability relating to the use or reliance on the information contained in this publication. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Serve You Rx.

*New Formulation of an Existing Product

Source: IPD Analytics, 2025

Key

Launched MM YYYY

Approved MM YYYY

Date

Month and year drug was launched

Month and year drug was approved

Updated release date

Withdrawn

CRL

EST LOE PROB

Drug has been withdrawn from FDA approval

Complete Response Letter - Incomplete FDA Application

Estimated Loss of Exclusivity Probability based on IPD Analytics' proprietary estimate of the probability of a generic launch, based on patent analysis and knowledge of generic launches